The patients were randomized 2:1:1 to receive WEGOVY 2.4 mg, WEGOVY 1.7 mg, or placebo
As these drugs become more accessible and democratized, as people get more comfortable taking them as a lifestyle choice, companies have to be there to support the consumer in that process, she says
Across large employers that cover the drugs for weight loss, many require participation in lifestyle or nutrition programs before coverage applies
A recent meta-analysis conducted among 101,028 individuals considered overweight or obese helped to quantify the large negative impact of obesity on MASLD [47]
Managing this with high-protein, high-fiber foods prevents it from sabotaging results
Resmetirom (Rezdiffra) has become the first medication specifically approved for MASH with moderate to advanced fibrosis (stages F2-F3) [FDA] [EMA]